



Company Overview

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has nine marketed prescription pharmaceutical products and multiple programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children's Hospital and Sentynt. For more information, visit www.fortressbiotech.com.

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Mar 18 2026, 8:30 AM EDT

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for \$205 Million

Feb 23 2026, 9:24 AM EST

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Feb 23 2026, 8:00 AM EST

Stock Overview

Symbol	FBIO
Exchange	Nasdaq
Market Cap	99.34m
Last Price	\$3.14
52-Week Range	\$1.32 - \$4.53

Investor Relations

Jaclyn Jaffe
Nicole McCloskey
T: 781-652-4500
ir@fortressbiotech.com

03/19/2026 08:00 PM EDT

Management Team

Lindsay A. Rosenwald, M.D.

Chairman, President and Chief Executive Officer

Michael S. Weiss

Executive Vice Chairman, Strategic Development

David Jin

Chief Financial Officer and Head of Corporate Development

Samuel Berry

General Counsel and Corporate Secretary

Fortress Biotech, Inc.

1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.